Mingzhe Xiao

The State Key Lab Of Translational Medicine And Innovative Drug Development
Nanjing, 210002, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

LIF Promotes Sec15b-Mediated STAT3 Exosome Secretion to Maintain Stem Cell Pluripotency in Mouse Embryonic Development.

LIF Promotes Sec15b-Mediated STAT3 Exosome Secretion to Maintain Stem Cell Pluripotency in Mouse Embryonic Development.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: July 13, 2024

Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma.

Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma.

Journal: Investigational new drugs

Published: March 24, 2023

SLIT mutations as potential predictive biomarkers for immunotherapy in NSCLC.

SLIT mutations as potential predictive biomarkers for immunotherapy in NSCLC.

Journal: Investigational new drugs

Published: November 29, 2022

A remarkable clinical response to immune checkpoint inhibitors of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity.

A remarkable clinical response to immune checkpoint inhibitors of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity.

Journal: Oral oncology

Published: September 26, 2022

Genomic profiling of non-small cell lung cancer with the rare pulmonary lymphangitic carcinomatosis and clinical outcome of the exploratory anlotinib treatment.

Genomic profiling of non-small cell lung cancer with the rare pulmonary lymphangitic carcinomatosis and clinical outcome of the exploratory anlotinib treatment.

Journal: Frontiers in oncology

Published: July 12, 2022

PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.

PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.

Journal: Cell proliferation

Published: April 14, 2022

Long non-coding RNA TDRG1 aggravates colorectal cancer stemness by binding with miR-873-5p to upregulate PRKAR2.

Long non-coding RNA TDRG1 aggravates colorectal cancer stemness by binding with miR-873-5p to upregulate PRKAR2.

Journal: Environmental toxicology

Published: March 21, 2022

SIRT4-Catalyzed Deacetylation of Axin1 Modulates the Wnt/β-Catenin Signaling Pathway.

SIRT4-Catalyzed Deacetylation of Axin1 Modulates the Wnt/β-Catenin Signaling Pathway.

Journal: Frontiers in oncology

Published: February 22, 2022

A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.

A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.

Journal: Investigational new drugs

Published: January 20, 2022

Locally advanced undifferentiated sarcomatoid carcinoma of the right maxillary sinus with PDCD6-TERT fusion: A rare case report.

Locally advanced undifferentiated sarcomatoid carcinoma of the right maxillary sinus with PDCD6-TERT fusion: A rare case report.

Journal: Oral oncology

Published: June 09, 2021

Chr1 95026203-ALK, a novel intergenic fusion identified in a patient with lung adenocarcinoma with nodular ground-glass opacity.

Chr1 95026203-ALK, a novel intergenic fusion identified in a patient with lung adenocarcinoma with nodular ground-glass opacity.

Journal: Journal of thoracic disease

Published: April 19, 2021

A novel DPP10 (intergenic)-NTRK3 fusion in a patient with facial malignant melanoma and potentially benefit from NTRK inhibitors.

A novel DPP10 (intergenic)-NTRK3 fusion in a patient with facial malignant melanoma and potentially benefit from NTRK inhibitors.

Journal: Oral oncology

Published: March 22, 2021

Showing 1-12 of 26

Last Updated: 09/26/2026